ReviewNature reviews. Nephrology2012
Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- An integrated network pharmacology and proteomics approach reveals the anti-fibrotic effect of Fushen Granule on peritoneal fibrosis.BMC complementary medicine and therapies · 2026Article
- The epidemiology of encapsulating peritoneal sclerosis in an era of biocompatible neutral peritoneal dialysis solution in Japan.Clinical and experimental nephrology · 2025Article
- Integrating single-cell RNA-seq, bulk RNA-seq and network pharmacology reveals protective effect of salidroside in peritoneal dialysis-associated peritoneal fibrosis.Frontiers in pharmacology · 2025Article
- IL-1β may be an indicator of peritoneal deterioration after healing of peritoneal dialysis-associated peritonitis.BMC nephrology · 2023Article
- Tissue Sodium Accumulation Induces Organ Inflammation and Injury in Chronic Kidney Disease.International journal of molecular sciences · 2023Review
- Single-cell sequencing reveals peritoneal environment and insights into fibrosis in CAPD patients.iScience · 2023Article
- The prognosis and risk factors of baseline high peritoneal transporters on patients with peritoneal dialysis.Journal of cellular and molecular medicine · 2021Article
- Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6.Stem cell research & therapy · 2021Article
- Loosening of the mesothelial barrier as an early therapeutic target to preserve peritoneal function in peritoneal dialysis.Kidney research and clinical practice · 2020Review
- Expression of XBP1s in peritoneal mesothelial cells is critical for inflammation-induced peritoneal fibrosis.Scientific reports · 2019Article
- ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose.Journal of cellular and molecular medicine · 2019Article
- CD147 expression in peritoneal injury.Clinical and experimental nephrology · 2017Article
- Local amplifiers of IL-4Rα-mediated macrophage activation promote repair in lung and liver.Science (New York, N.Y.) · 2017Article
- Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.Journal of the American Society of Nephrology : JASN · 2016Article
- Encapsulating peritoneal sclerosis in an Italian center: thirty year experience.Journal of nephrology · 2016Article
- Selective Blocking of TNF Receptor 1 Attenuates Peritoneal Dialysis Fluid Induced Inflammation of the Peritoneum in Mice.PloS one · 2016Article
- Deficiency of endothelial nitric oxide signaling pathway exacerbates peritoneal fibrosis in mice.Clinical and experimental nephrology · 2015Article
- A microrna screen to identify regulators of peritoneal fibrosis in a rat model of peritoneal dialysis.BMC nephrology · 2015Article
- A pathogenetic role for endothelin-1 in peritoneal dialysis-associated fibrosis.Journal of the American Society of Nephrology : JASN · 2015Article
- The PPARβ/δ agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFκB pathway in rats.Inflammation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Functional deterioration of the peritoneal membrane in patients on peritoneal dialysis has been described as being the result of a combination of neoangiogenesis and fibrosis. Glucose, glucose degradation products, and the unphysiological pH of the dialysate solution contribute to these changes. Although newer solutions clearly perform better in terms of their biocompatibility in an in vitro setting and in animal models, the benefit of such solutions over older solutions in the clinical setting is so far unproven. The difficulties in showing a benefit of the newer, more biocompatible solutions in the clinical setting can be explained by the fact that other factors also affect the properties of the peritoneal membrane. These factors are often neglected in clinical studies, which results in unnoticed differences in case-mix and blurs the potential impact of the novel solutions. However, many of these factors are modifiable, and attention should be paid to them in clinical practice to maintain the integrity of the peritoneal membrane. This Review focuses on factors that potentially influence the integrity of the peritoneal membrane, other than those associated with the peritoneal dialysis fluid itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.